Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KLRA

Kailera Therapeutics Inc

Apr 20 • 04:00PM ET

24.61

-1.39 -5.35 %

Healthcare • Biotechnology • USA • NASD

Today, 4:40 PMKailera Therapeutics announces the closing of its IPO, including full exercise of the underwriters’ option, raising $718.8 million in gross proceeds at $16 per share.

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	84.62M	Perf Week	-
Market Cap	2.08B	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	18.05%	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-5.35%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	27.50 -10.51%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	23.70 3.84%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	4.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-2.75%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-2.75%	Rel Volume	0.17	Prev Close	26.00
Employees	145	LT Debt/Eq	-	Earnings	-	SMA200	-2.75%	Avg Volume	8.11M	Price	24.61
IPO	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,340,356	Change	-5.35%

Today 04:05PM

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

(GlobeNewswire) -5.35%

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:10 PM
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:08 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:01 PM
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRA

Kailera Therapeutics Inc

Upgrade your Finviz experience